细胞衰老参与脓毒症所致肌无力且二甲双胍可改善
研究采用盲肠结扎穿孔或腹腔注射LPS构建脓毒症小鼠模型,并在体外用LPS处理成肌细胞,发现脓毒症小鼠体重和肌力显著下降,RNA-seq显示多种细胞衰老基因参与,衰老相关基因p53和p21表达上调,胫骨前肌SA-β-gal染色和天狼星红胶原染色增强。siRNA抑制p53可显著减少LPS处理后SA-β-gal阳性成肌细胞,提示脓毒症诱导的细胞衰老依赖p53。二甲双胍减轻小鼠成肌细胞和骨骼肌的细胞衰老,并改善脓毒症小鼠肌力。作者据此提出二甲双胍是ICU获得性衰弱的潜在治疗策略。
要点
- 脓毒症小鼠(盲肠结扎穿孔或腹腔注射LPS)体重和肌力显著下降,胫骨前肌SA-β-gal染色和天狼星红胶原染色增强。
- 脓毒症时衰老相关基因p53和p21表达均上调,RNA-seq显示多种细胞衰老基因参与。
- siRNA抑制p53可显著减少LPS处理后SA-β-gal阳性成肌细胞,提示脓毒症诱导的细胞衰老依赖p53。
- 二甲双胍减轻脓毒症时小鼠成肌细胞和骨骼肌的细胞衰老,并改善脓毒症小鼠肌力。
- 作者提出二甲双胍作为ICU获得性衰弱的潜在治疗策略,证据来自动物与细胞实验。
适用人群与场景
- 盲肠结扎穿孔或腹腔注射LPS诱导的脓毒症小鼠(体内实验)
- LPS处理的成肌细胞(体外实验)
处置流程与药物剂量
- 二甲双胍作为抗衰老剂在脓毒症小鼠和LPS处理成肌细胞中测试,可减轻细胞衰老并改善脓毒症小鼠肌力;原文未给出剂量、途径和疗程。
研究设计与关键结果
- 盲肠结扎穿孔或LPS诱导的脓毒症小鼠肌肉重量和肌力均显著下降。
- RNA-seq分析显示多种细胞衰老基因参与脓毒症,衰老相关基因p53和p21表达均上调。
- 胫骨前肌SA-β-gal染色和天狼星红胶原染色增强。
- siRNA抑制p53表达可显著减少LPS处理后SA-β-gal阳性成肌细胞数量,提示脓毒症诱导的细胞衰老依赖p53。
- 二甲双胍减轻脓毒症时小鼠成肌细胞和骨骼肌的细胞衰老,并改善脓毒症小鼠肌力。
证据类型、等级与局限
- 证据类型:动物实验与体外细胞实验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为二甲双胍是ICU获得性衰弱的潜在治疗策略;该结论来自脓毒症小鼠和成肌细胞实验,原文未给出临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: Sepsis is a life-threatening medical emergency, frequently complicated with intensive care unit-acquired weakness syndrome (ICU-AW). ICU-AW patients display flaccid weakness of the limbs, especially in the proximal limb muscles. However, little is known regarding its pathogenesis. Here, we aimed to identify the potential signaling pathway involved in ICU-AW regulation and identify a potential therapeutic drug for intervention. Methods: Both in vivo and in vitro septic mice were used. For the in vivo septic mice, either cecum ligation and puncture or intraperitoneal injection of LPS was conducted in mice. The body weight and muscle mass were then measured and recorded. Muscle strength was evaluated by limb grip strength test. The expression of proteins extracted from cells and muscles was checked through Western blot analysis. Quantitative reverse transcription-polymerase chain reaction was carried out to test the transcriptional level of genes. Senescence-associated β-galactosidase (SA-β-gal) staining and Sirius red for collagen staining were conducted. Metformin, as an antiaging agent, was then tested for any attenuation of sepsis-related symptoms. For in vitro sepsis modeling, myoblasts were treated with LPS, analyzed for senescence-related protein expression, and subsequently retested upon metformin treatment. Results: We found that both the weight and strength of muscle were dramatically reduced in cecum ligation and puncture- or LPS-induced septic mice. RNA-seq analysis revealed that various cellular senescent genes were involved in sepsis. In line with this, expression of senescence-related genes, p53 and p21 were both upregulated. Both SA-β-gal and Sirius red for collagen staining were enhanced in tibialis anterior muscles. Notably, inhibition of p53 expression by siRNA prominently reduced the number of SA-β-gal-positive myoblasts upon LPS treatment. This indicated sepsis-induced cellular senescence to be dependent on p53. Consistent with the function of metformin in antiaging, metformin attenuated cellular senescence in both murine myoblasts and skeletal muscles during sepsis. Muscle strength of septic mice was improved upon metformin treatment. Metformin intervention is therefore proposed as a potential therapeutic strategy for ICU-AW. Conclusion: Taken together, we revealed a previously unappreciated linkage between cellular senescence and sepsis-induced muscle weakness and propose metformin as a potential therapeutic drug for the treatment of ICU-AW.
参考来源
- Chen J, Chen XY, Cong XX, et al. CELLULAR SENESCENCE IMPLICATED IN SEPSIS-INDUCED MUSCLE WEAKNESS AND AMELIORATED WITH METFORMIN. Shock. 2023. PMID: 36719431. doi:10.1097/SHK.0000000000002086
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。